NEW YORK (GenomeWeb) – OncoDNA said today that a number of private health insurers, including BUPA Global Insurance, will now reimburse for its OncoStrat&Go testing in the United Kingdom.

OncoStrat&Go is a combined liquid biopsy and tissue test intended to provide a complete genetic profile of a patient's tumor to predict response to targeted, immunotherapeutic, and chemotherapy treatments.

BUPA Global has created a specific code for the reimbursement of the test, while other UK insurers will use a generic code, OncoDNA said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.